In agreement with our data in mouse tumor models, IRG1 expression exhibited a negative correlation with tumor-infiltrating CD8+ T cells in clinical samples of patients with HCC after immunotherapy (Fig. 5, E and G), further suggesting that targeting IRG1/ACOD1 represents a promising strategy for enhancing the efficacy of cancer immunotherapy. This evidence concerns the gene CD8A and cancer.